Crizalk 250mg Capsule

About

Crizalk 250mg Capsule, containing crizotinib, is an anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinase inhibitor. It functions by selectively blocking the activity of these specific receptor tyrosine kinases, which are frequently aberrantly activated in certain types of cancer due to chromosomal rearrangements. In ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC), these genetic fusions lead to uncontrolled cell growth and survival. By inhibiting ALK and ROS1, crizotinib effectively disrupts these oncogenic signaling pathways, leading to tumor regression and improved patient outcomes. This medication represents a significant advancement in targeted therapy for patients whose tumors harbor these specific genetic alterations, offering a more personalized treatment approach.

Crizalk 250mg Capsule is an oral medication that has demonstrated substantial efficacy in patients with metastatic NSCLC who have ALK or ROS1 rearrangements. Its targeted mechanism helps to minimize damage to healthy cells compared to traditional chemotherapy, although it still carries a distinct profile of side effects. Patients undergoing treatment with crizotinib require careful monitoring for potential adverse events, including visual disturbances, gastrointestinal issues, and liver enzyme elevations. Regular assessments are crucial to ensure optimal therapeutic benefit and manage any emerging toxicities effectively.

Uses

• ALK-positive metastatic non-small cell lung cancer (NSCLC)
• ROS1-positive metastatic non-small cell lung cancer (NSCLC)
• NTRK-positive solid tumors (off-label or in specific contexts)
• Other ALK-positive malignancies (e.g., anaplastic large cell lymphoma)

Directions For Use

Take orally, usually twice daily, with or without food, as directed by your doctor. Swallow capsules whole.

Benefits

• Highly effective in ALK-positive NSCLC.
• Significant response rates in ROS1-positive NSCLC.
• Oral administration for patient convenience.
• Offers a targeted therapy approach.
• Improves progression-free survival.
• Can lead to durable responses in selected patients.

Side Effects

• Visual disturbances (e.g., blurred vision, flashes of light)
• Nausea
• Diarrhea
• Vomiting
• Constipation
• Edema (swelling)
• Fatigue
• Decreased appetite
• Liver enzyme elevation
• Bradycardia (slow heart rate)
• Interstitial lung disease (ILD)
• QT interval prolongation

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but moderation is generally advised during cancer treatment.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if crizotinib is excreted in human milk and could harm the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary, and liver function should be closely monitored.
• Kidney - Use with caution in patients with severe renal impairment; dose adjustments may be required, and kidney function should be regularly assessed.
• Lung - Monitor for new or worsening pulmonary symptoms, as interstitial lung disease (ILD) or pneumonitis can occur and may be severe or fatal.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.